Skip to main content
Log in

Pharmacokinetics of intravenous and intraperitoneal ceftriaxone in chronic ambulatory peritoneal dialysis

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The kinetics of ceftriaxone was investigated in 8 patients without infection, who were receiving continuous ambulatory peritoneal dialysis (CAPD). Ceftriaxone 1 g was injected i.v. and 1 g was given intraperitoneally in the CAPD fluid during a 4-h dwell time. Ceftriaxone was assayed by HPLC. After intravenous administration, the kinetic parameters of ceftriaxone were: plasma t1/2, 12.3 h, total plasma clearance, 14.0 ml/min, volume of distribution at steady state 0.18 l/kg, and peritoneal clearance 0.59 ml/min. Over 72 hours only 5.5% of the dose was eliminated by the peritoneal route. After intraperitoneal administration, ceftriaxone rapidly appeared in serum; the absorption t1/2 was 1.1 h and the mean peak concentration was 38.8 µg/ml. The absorption of ceftriaxone from the peritoneal space was 39%. A single 1.0 g IP dose led to serum and dialysate concentrations of ceftriaxone above the minimum inhibitory concentration for susceptible pathogens for 24 hours.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Albin HC, Demotes-Mainard FM, Bouchet JL, Vinçon GA, Martin-Dupont C (1985) Pharmacokinetics of intravenous and intraperitoneal cefotaxime in chronic ambulatory peritoneal dialysis. Clin Pharmacol Ther 38: 285–289

    Google Scholar 

  2. Albin HC, Ragnaud JM, Demotes-Mainard F, Vinçon G, Wone C (1986) Pharmacokinetics of intravenous and intraperitoneal moxalactam in chronic ambulatory peritoneal dialysis Eur J Clin Pharmacol 30: 299–302

    Google Scholar 

  3. Arvidsson A, Alvan G, Anvelin B, Borga O, Nord CE (1982) Ceftriaxone renal and biliary excretion and effect on colon microflora. J Antimicrob Chemother 10: 207–215

    Google Scholar 

  4. Arvidsson A, Alvan G, Tranaeus A, Malmborg AS (1985) Pharmacokinetic studies of cefoxitin in continuous ambulatory peritoneal dialysis. Eur J Clin Pharmacol 28: 333–337

    Google Scholar 

  5. Bunke CM, Aronoff GR, Brier HE, Sloan RS, Luft FC (1983) Cefazolin and cephalexin kinetics in continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 33: 66–72

    Google Scholar 

  6. Cohen D, Appel GB, Scully B, Neu HC (1983) Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis. Antimicrob. Agents Chemother 24: 529–532

    Google Scholar 

  7. Gibson TP, Matusals E, Nelson LD, Briges WA (1976) Artificial kidneys and clearance calculations. Clin Pharmacol Ther 20: 720–726

    Google Scholar 

  8. Gomeni R (1984) PHARM — An interactive graphic program for individual and population pharmacokinetic parameter estimation. Comput Biol Med 14: 25–34

    Google Scholar 

  9. Gross ML, Somani P, Ribner BS, Raeader R, Freimer EM, Kiggins TT (1983) Ceftizoxime elimination kinetics in continuous ambulatory peritoneal dialysis. Clin Pharmacol 34: 673–680

    Google Scholar 

  10. Holder JE, Galeazzi RL, Frey B, Rudhardt M, Seiler AJ (1984) Pharmacokinetics of cefoperazone in patients undergoing chronic ambulatory peritoneal dialysis: clinical and pathophysiological implications. Eur J Clin Pharmacol 26: 609–612

    Google Scholar 

  11. McIntosh ME, Smith WGJ, Junor BJR, Forrest G, Brodie MJ (1985) Increased peritoneal permeability in patients with peritonitis undergoing continuous ambulatory peritoneal dialysis. Eur J Clin Pharmacol 28: 187–191

    Google Scholar 

  12. McNamara PJ, Stoeckel K, Ziegler WH (1982) Pharmacokinetics of ceftriaxone following intravenous administration of a 3 g dose. Eur J Clin Pharmacol 22: 71–75

    Google Scholar 

  13. Patel IH, Chen S, Parsonnet M, Hackmann MR, Brooks MA, Konikoff J, Kaplan SA (1981) Pharmacokinetics of ceftriaxone in humans. Antimicrob Agents Chemother 20: 634–641

    Google Scholar 

  14. Patel IH, Sugihara JG, Weinfeld RE, Wong EGC, Siemsen AW, Berman SJ (1984) Ceftriaxone pharmacokinetics in patients with various degrees of renal impairment. Antimicrob Agents Chemother 25: 438–442

    Google Scholar 

  15. Petersen J, Stewart RDM, Catton GRD, Edward N (1985) Pharmacokinetics of intraperitoneal cefotaxime treatment of peritonitis in patients continuous ambulatory peritoneal dialysis. Nephron 40: 79–82

    Google Scholar 

  16. Pickup ME, Bird HA, Lowe JR, Lees L, Wright V (1981) Pharmacokinetic and tolerance study of Ro 13-9904, a new cephalosporin antibiotic. Br J Clin Pharmacol 12: 111–115

    Google Scholar 

  17. Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Ramai JJ Jr (1982) Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults. Antimicrob Agents Chemother 22: 816–823

    Google Scholar 

  18. Stoeckel K (1981) Pharmacokinetics of Rocephin, a highly active new cephalosporin with an exceptionnally long biological half-life. Chemotherapy 27 [Suppl 1]: 42–46

    Google Scholar 

  19. Stoeckel K, Mc Namara PJ, Hoppe-Seyler G, Blumberg A, Keller E (1983) Single-dose ceftriaxone kinetics in functionally anephric patients. Clin Pharmacol Ther 33: 633–641

    Google Scholar 

  20. Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ (1984) Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis. Antimicrob Agents Chemother 25: 83–87

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Albin, H., Ragnaud, J.M., Demotes-Mainard, F. et al. Pharmacokinetics of intravenous and intraperitoneal ceftriaxone in chronic ambulatory peritoneal dialysis. Eur J Clin Pharmacol 31, 479–483 (1986). https://doi.org/10.1007/BF00613528

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00613528

Key words

Navigation